文献速递肝病消化内镜

胃内球囊置入可显著改善非酒精性脂肪性肝炎的代谢与组织学指标

Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-30

6个月后平均总体重下降11.7%±7.7%,90%患者NAS改善,50%达到FDA批准的NASH缓解和纤维化改善终点,安全性良好。

要点

  • 胃内球囊置入6个月后NASH活动度评分改善率达90%
  • 50%患者达到FDA批准的NASH缓解与纤维化改善联合终点
  • 体重下降百分比与组织学改善无相关性

核心结论

  • 胃内球囊置入联合饮食运动方案可显著改善NASH患者的代谢和组织学指标,且安全性良好。

主要发现

  • 20例可评估患者中18例(90%)NAS改善,中位下降3分(范围1-4分),16例(80%)改善≥2分。
  • 15%患者纤维化分期改善1.17期,10/20例(50%)磁共振弹性成像检测的纤维化改善1.5期。
  • 50%患者达到FDA批准的NASH缓解和纤维化改善终点。
  • 总体重下降百分比与NAS或纤维化改善无相关性;除术后疼痛(5%)外未报告严重不良事件。

临床怎么用

  • 对于早期肝纤维化的肥胖NASH患者,胃内球囊置入可作为联合饮食运动方案的减重和肝脏改善手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Obese patients with nonalcoholic steatohepatitis (NASH) are at risk for cirrhosis if significant weight loss is not achieved. The single fluid-filled intragastric balloon (IGB) induces meaningful weight loss and might be used in NASH treatment. We performed an open-label prospective study to evaluate the effects of IGB placement on metabolic and histologic features of NASH. METHODS: Twenty-one patients with early hepatic fibrosis (81% female; mean age, 54 years; average body mass index, 44 kg/m2) underwent magnetic resonance elastography (MRE) and endoscopic ultrasound with core liver biopsy collection at time IGB placement and removal at a single center from October 2016 through March 2018. The primary outcome measure was the changes in liver histology parameters after IGB, including change in nonalcoholic fatty liver disease activity score (NAS) and fibrosis score. We also evaluated changes in weight, body mass index, waist to hip ratio, aminotransaminases, fasting levels of lipids, fasting glucose, glycosylated hemoglobin, and MRE-detected liver stiffness. RESULTS: Six months after IGB, patients' mean total body weight loss was 11.7% ± 7.7%, with significant reductions in HbA1c (1.3% ± 0.5%) (P = .02). Waist circumference decreased by 14.4 ± 2.2 cm (P = .001). NAS improved in 18 of 20 patients (90%), with a median decrease of 3 points (range, 1-4 points); 16 of 20 patients (80%) had improvements of 2 points or more. Fibrosis improved by 1.17 stages in 15% of patients, and MRE-detected fibrosis improved by 1.5 stages in 10 of 20 patients (50%). Half of patients reached endpoints approved by the Food and Drug Administration of for NASH resolution and fibrosis improvement. Percent total body weight loss did not correlate with reductions in NAS or fibrosis. Other than post-procedural pain (in 5% of patients), no serious adverse events were reported. CONCLUSION: In a prospective study, IGB facilitated significant metabolic and histologic improvements in NASH. IGB appears to be safe and effective for NASH management when combined with a prescribed diet and exercise program. ClinicalTrials.gov no: NCT02880189.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bazerbachi F, Vargas EJ, Rizk M, et al. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020. PMID: 32360804. doi:10.1016/j.cgh.2020.04.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。